Did you know blastoid (B) and pleomorphic (P) variants of #MantleCellLymphoma exhibit distinct biological differences? A recent study (n=102) showed significantly higher Ki-67, 𝘕𝘖𝘛𝘊𝘏1 and median OS in B-MCL compared with P-MCL. Should these variants be designated separately?

** sigh **

Life goes on, right?

Until it doesn't.

#Cancer #Lymphoma #MantleCellLymphoma #NonHodgkinsLymphoma

Watch Prof Wojciech Jurczak discuss some of the key risk factors in patients with #MantleCellLymphoma .

In clinical practice, mantle cell lymphoma (MCL) can be classified into two groups based on nucleotide metabolism expression: a group with abnormal expression and adverse prognosis, and the other with superior prognosis.

onlinelibrary.wiley.com/doi/10.1111/bj…
#lymsm #mantlecelllymphoma

Survival outcomes in #MantleCellLymphoma ( #MCL ) have improved in the past two decades. A prospective cohort study (n=183) reported 5-year overall survival (OS) rates of 31%, 37% and 67% for the periods 2003–2009 (Era 1), 2010–2014 (Era 2) and 2015–2021 (Era 3), respectively.

The incidence of #MantleCellLymphoma ( #MCL ) is significantly higher in men than in women. But did you know female patients with comorbidities experience a higher proportion of non-lymphoma deaths compared to males? What do you think may be the underlying cause for this?

The health-related quality of life burden (HRQoL) associated with #MantleCellLymphoma ( #MCL ) is substantial. What more can be done to improve or maintain HRQoL in these patients?

These two MD Anderson docs delivered the best news today to my hubbs. Continued remission! Who in the world cares more about mantle cell lymphoma? Michael Wang, MD Charles Gaulin MD MD Anderson Cancer Center #mantlecelllymphoma

Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax

onlinelibrary.wiley.com/doi/10.1002/jh…
#mantlecelllymphoma #MCL#lymsm BSH - Haematology

Machine learning (ML) may be used to enhance prognostic accuracy in #MantleCellLymphoma . Incorporating clinical, cytogenetic and genomic data into the ML model could discriminate  between patients with indolent or responsive #MCL and those with aggressive disease.

👏🏼👏🏼Congratulations clementine sarkozy et al.
Journal of Clinical Oncology #lymphoma #mantlecelllymphoma #MCL #LYSA #lymsm

Dr M. Wang Michael Wang, MD defending the use of chemo-free regimens as fronline approach for #mantlecelllymphoma at #17ICML . So inspiring!

FDG-PET/CT has prognostic value in patients with #MantleCellLymphoma . A recent study of 59 patients reported that FDG-PET/CT radiomics at diagnosis predicted minimal residual disease status. Could FDG-PET/CT radiomics be the future of MRD detection in #MCL ?

Atypical cyclin D1-negative #MantleCellLymphoma occurs in 1–2% of patients with #MCL . Is there a role for PET-CT imaging in the diagnosis of these rare cases?

Updated results & subgroup analysis w/ 2yrs of survival follow-up from the phase 1/2 BRUIN study, investigating a highly selective, non-covalent (reversible) BTKi in pts w/ #MantleCellLymphoma previously treated w/ a covalent BTKi.

Presented at #EHA2023 : e.lilly/4602uF1

Prognostic factors in #MantleCellLymphoma are continually evolving, highlighting current unmet needs in patient assessment and care. Which factors do you consider most important when identifying high-risk patients with #MCL ?

CURRENTLY ENROLLING #ClinicalTrials : A phase 3, open-label, randomized study of our non-covalent (reversible) BTK inhibitor in patients w/ previously treated, BTKi naïve, #MantleCellLymphoma .

View detailed trial & enrollment info here: e.lilly/3PYOLZu

#lymsm #lymphoma

SCI member David Miklos & others found KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory #MantleCellLymphoma . bit.ly/3L9gkwq #CARTcells

This #BloodCancerAwarenessMonth we're bringing attention to #MantleCellLymphoma , a rare form of non-Hodgkin #lymphoma w/ significant unmet needs.

HCPs - Visit our #MedEd site for #MCL resources including disease overviews, adherence strategies, and more: e.lilly/3Ry0Sxr

👏🏼 Bravo to all authors including #WomenInLymphoma

Bravo to all authors including #WomeninLymphoma
Eva Hoster #ChristianePott #MarieHeleneDelfauLarue #CatherineThieblemont ascopubs.org/doi/abs/10.120……
#lymphoma #MantleCellLymphoma #MCL
Journal of Clinical Oncology
ascopubs.org/doi/abs/10.120…